OPRX Relative Valuation
OPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OPRX is overvalued; if below, it's undervalued.
Historical Valuation
OptimizeRx Corp (OPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 17.59 is considered Undervalued compared with the five-year average of 59.70. The fair price of OptimizeRx Corp (OPRX) is between 16.16 to 63.96 according to relative valuation methord. Compared to the current price of 13.85 USD , OptimizeRx Corp is Undervalued By 14.28%.
Relative Value
Fair Zone
16.16-63.96
Current Price：13.85
14.28%
Undervalued
17.59
PE
1Y
3Y
5Y
13.63
EV/EBITDA
OptimizeRx Corp. (OPRX) has a current EV/EBITDA of 13.63. The 5-year average EV/EBITDA is 54.19. The thresholds are as follows: Strongly Undervalued below -41.19, Undervalued between -41.19 and 6.50, Fairly Valued between 101.88 and 6.50, Overvalued between 101.88 and 149.57, and Strongly Overvalued above 149.57. The current Forward EV/EBITDA of 13.63 falls within the Historic Trend Line -Fairly Valued range.
49.18
EV/EBIT
OptimizeRx Corp. (OPRX) has a current EV/EBIT of 49.18. The 5-year average EV/EBIT is 125.27. The thresholds are as follows: Strongly Undervalued below -593.43, Undervalued between -593.43 and -234.08, Fairly Valued between 484.61 and -234.08, Overvalued between 484.61 and 843.96, and Strongly Overvalued above 843.96. The current Forward EV/EBIT of 49.18 falls within the Historic Trend Line -Fairly Valued range.
2.03
PS
OptimizeRx Corp. (OPRX) has a current PS of 2.03. The 5-year average PS is 5.93. The thresholds are as follows: Strongly Undervalued below -5.10, Undervalued between -5.10 and 0.41, Fairly Valued between 11.44 and 0.41, Overvalued between 11.44 and 16.96, and Strongly Overvalued above 16.96. The current Forward PS of 2.03 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
OptimizeRx Corp. (OPRX) has a current P/OCF of 0.00. The 5-year average P/OCF is 54.90. The thresholds are as follows: Strongly Undervalued below -163.27, Undervalued between -163.27 and -54.18, Fairly Valued between 163.99 and -54.18, Overvalued between 163.99 and 273.07, and Strongly Overvalued above 273.07. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
OptimizeRx Corp. (OPRX) has a current P/FCF of 0.00. The 5-year average P/FCF is 74.14. The thresholds are as follows: Strongly Undervalued below -159.43, Undervalued between -159.43 and -42.65, Fairly Valued between 190.93 and -42.65, Overvalued between 190.93 and 307.72, and Strongly Overvalued above 307.72. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
OptimizeRx Corp (OPRX) has a current Price-to-Book (P/B) ratio of 1.89. Compared to its 3-year average P/B ratio of 1.73 , the current P/B ratio is approximately 9.43% higher. Relative to its 5-year average P/B ratio of 3.84, the current P/B ratio is about -50.75% higher. OptimizeRx Corp (OPRX) has a Forward Free Cash Flow (FCF) yield of approximately 5.08%. Compared to its 3-year average FCF yield of 0.97%, the current FCF yield is approximately 423.56% lower. Relative to its 5-year average FCF yield of 0.73% , the current FCF yield is about 594.97% lower.
1.89
P/B
Median3y
1.73
Median5y
3.84
5.08
FCF Yield
Median3y
0.97
Median5y
0.73
Competitors Valuation Multiple
The average P/S ratio for OPRX's competitors is 3.16, providing a benchmark for relative valuation. OptimizeRx Corp Corp (OPRX) exhibits a P/S ratio of 2.03, which is -35.77% above the industry average. Given its robust revenue growth of 22.33%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OPRX increased by 149.55% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 2.02K to 6.76K.
The secondary factor is the Revenue Growth, contributed 22.33%to the performance.
Overall, the performance of OPRX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is OptimizeRx Corp (OPRX) currently overvalued or undervalued?
OptimizeRx Corp (OPRX) is now in the Undervalued zone, suggesting that its current forward PE ratio of 17.59 is considered Undervalued compared with the five-year average of 59.70. The fair price of OptimizeRx Corp (OPRX) is between 16.16 to 63.96 according to relative valuation methord. Compared to the current price of 13.85 USD , OptimizeRx Corp is Undervalued By 14.28% .
What is OptimizeRx Corp (OPRX) fair value?
OPRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of OptimizeRx Corp (OPRX) is between 16.16 to 63.96 according to relative valuation methord.
How does OPRX's valuation metrics compare to the industry average?
The average P/S ratio for OPRX's competitors is 3.16, providing a benchmark for relative valuation. OptimizeRx Corp Corp (OPRX) exhibits a P/S ratio of 2.03, which is -35.77% above the industry average. Given its robust revenue growth of 22.33%, this premium appears sustainable.
What is the current P/B ratio for OptimizeRx Corp (OPRX) as of Jan 08 2026?
As of Jan 08 2026, OptimizeRx Corp (OPRX) has a P/B ratio of 1.89. This indicates that the market values OPRX at 1.89 times its book value.
What is the current FCF Yield for OptimizeRx Corp (OPRX) as of Jan 08 2026?
As of Jan 08 2026, OptimizeRx Corp (OPRX) has a FCF Yield of 5.08%. This means that for every dollar of OptimizeRx Corp’s market capitalization, the company generates 5.08 cents in free cash flow.
What is the current Forward P/E ratio for OptimizeRx Corp (OPRX) as of Jan 08 2026?
As of Jan 08 2026, OptimizeRx Corp (OPRX) has a Forward P/E ratio of 17.59. This means the market is willing to pay $17.59 for every dollar of OptimizeRx Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for OptimizeRx Corp (OPRX) as of Jan 08 2026?
As of Jan 08 2026, OptimizeRx Corp (OPRX) has a Forward P/S ratio of 2.03. This means the market is valuing OPRX at $2.03 for every dollar of expected revenue over the next 12 months.